Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Melinda L TelliJessica HellyerWilliam AudehKristin C JensenShikha BoseKirsten M TimmsAlexander GutinVictor AbkevichRebecca N PetersonChris NeffElisha HughesZaina SangaleJoshua JonesAnne-Renee HartmanPei-Jen ChangShaveta VinayakRichard WenstrupJames M FordPublished in: Breast cancer research and treatment (2017)
HR deficiency status is significantly associated with response to standard neoadjuvant chemotherapy in TNBC. This observation is consistent with the mechanisms of action of doxorubicin and cyclophosphamide as DNA damaging agents.